|Videos|October 18, 2022
Dr. Chughtai discusses new pilot study on Rezum treatment for BPH
Author(s)Urology Times staff
“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.
Advertisement
In this video, Bilal Chughtai, MD, an associate professor of Urology at Weill Cornell Medical College, discusses the background and findings of his recent paper, "Pilot study of ‘less is more’ Rezum for treatment of BPH."
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Sarah Azari, MD, on early sexual health education for women with bladder cancer
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5